<div id="readability-page-1"><p>Alliancebernstein L.P. cut its stake in  Zoetis Inc. (NYSE:ZTS - Free Report) by 65.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,745,037 shares of the company's stock after selling 7,111,354 shares during the quarter. Alliancebernstein L.P. owned 0.85% of Zoetis worth $584,039,000 at the end of the most recent quarter.</p><ul><li>Which Pet Stock Should Get Your Tail Wagging in 2024?</li></ul><p>Several other hedge funds and other institutional investors have also bought and sold shares of ZTS. Soros Capital Management LLC raised its holdings in  Zoetis by 80.4% in the second quarter. Soros Capital Management LLC now owns 31,468 shares of the company's stock worth $4,907,000 after purchasing an additional 14,027 shares during the period.  HUB Investment Partners LLC increased its position in shares of  Zoetis by 64.5% in the 2nd quarter. HUB Investment Partners LLC now owns 2,241 shares of the company's stock valued at $350,000 after buying an additional 879 shares in the last quarter.  Ieq Capital LLC increased its position in shares of  Zoetis by 153.1% in the 2nd quarter. Ieq Capital LLC now owns 85,842 shares of the company's stock valued at $13,387,000 after buying an additional 51,924 shares in the last quarter.  ICW Investment Advisors LLC raised its stake in  Zoetis by 6.9% during the 2nd quarter. ICW Investment Advisors LLC now owns 5,624 shares of the company's stock worth $877,000 after buying an additional 363 shares during the period.  Finally, Treasurer of the State of North Carolina lifted its holdings in  Zoetis by 0.8% during the second quarter. Treasurer of the State of North Carolina now owns 208,458 shares of the company's stock worth $32,509,000 after acquiring an additional 1,731 shares in the last quarter. Institutional investors own  92.80% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>ZTS has been the subject of a number of research analyst reports. JPMorgan Chase &amp; Co. decreased their target price on Zoetis from $230.00 to $200.00 and set an &#34;overweight&#34; rating for the company in a research note on Wednesday, November 5th. UBS Group cut their price objective on Zoetis from $158.00 to $141.00 and set a &#34;neutral&#34; rating on the stock in a report on Wednesday, November 5th. Barclays began coverage on Zoetis in a research note on Monday. They set an &#34;equal weight&#34; rating and a $136.00 target price for the company. KeyCorp began coverage on shares of Zoetis in a research note on Thursday, November 20th. They issued a &#34;sector weight&#34; rating on the stock. Finally, Morgan Stanley reduced their price target on shares of Zoetis from $211.00 to $175.00 and set an &#34;overweight&#34; rating for the company in a report on Monday, November 10th. Five investment analysts have rated the stock with a Buy rating and seven have issued  a Hold rating to the company's stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $164.20.</p><ul><li>MarketBeat Week in Review – 07/31 - 08/04</li></ul><p><b>Read Our Latest Research Report on ZTS</b></p><h2>Zoetis Price Performance</h2><p>NYSE ZTS opened at $117.54 on Friday. The firm's 50 day moving average is $131.51 and its 200-day moving average is $146.53. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $51.80 billion, a PE ratio of 19.79, a price-to-earnings-growth ratio of 2.45 and a beta of 0.97. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $181.85. </p><ul><li>Rising Dividend Make Zoetis a Doggone Winner</li></ul><p>Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter last year, the firm earned $1.58 earnings per share. The firm's revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS.  Equities research analysts anticipate that  Zoetis Inc. will post 6.07 earnings per share for the current fiscal year. </p><h2>Zoetis Increases Dividend</h2><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.8%. This is a boost from Zoetis's previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis's payout ratio is currently 33.67%. </p><h2>About Zoetis</h2> (Free Report)<p>Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Zoetis</li><li>How to Choose Top Rated Stocks</li><li>3 Recently Downgraded Stocks to Avoid in 2026</li><li>Basic Materials Stocks Investing</li><li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li><li>How to Start Investing in Real Estate</li><li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li></ul><p><strong>Want to see what other hedge funds are holding ZTS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Zoetis Right Now?</h2><p>Before you consider Zoetis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.</p><p>While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Alliancebernstein L.P. reduced its stake in Zoetis Inc. by 65.5% in Q2, owning 0.85% worth $584.04 million. Other investors adjusted their positions in Zoetis, with Soros Capital Management increasing its holdings by 80.4%. Analysts have mixed ratings, with a consensus "Hold" and a price target of $164.20. Zoetis reported Q3 earnings of $1.70 per share, beating estimates, and announced a quarterly dividend of $0.53 per share.</p>

Alliancebernstein L.P. Has $584.04 Million Position in Zoetis Inc. $ZTS